Criteria | RA, n = 8 | Others, n = 7 |
---|---|---|
Age, yrs, mean | 64.6 | 75.6 |
Female | 6 (75) | 6 (85) |
BP, mo, mean | 48.8 | 48 |
BP administration | ||
Alendronate | 3 (37.5) | 3 (42.9) |
Risedronate | 2 (25) | 1 (14.3) |
Ibandronate | 1 (12.5) | 1 (14.3) |
Zoledronate | 0 | 1 (14.3) |
Zoledronate/pamidronate* | 1 (12.5) | 0 |
Alendronate/ibandronate* | 1 (12.5) | 0 |
Alendronate/risedronate* | 0 | 1 (14.3) |
Steroid | ||
No | 3 (37.5) | 7 (100) |
Yes | 5 (62.5) | 0 |
Trigger event | ||
Dental extraction | 7 (87.5) | 6 (85.7) |
Spontaneous | 1 (12.5) | 1 (14.3) |
Involved site | ||
Mandible | 5 (62.5) | 4 (57.1) |
Maxilla | 3 (37.5) | 3 (42.9) |
BRONJ stage | ||
Stage 1 (%) | 12.5 | 0 |
Stage 2 (%) | 62.5 | 100 |
Stage 3 (%) | 25 | 0 |
BRONJ treatment | ||
Antibiotics and surgery | 5 (62.5) | 5 (71.4) |
Antibiotics | 3 (37.5) | 2 (28.6) |
Complete healing, mo, mean | 12.5 | 10.7 |
↵* Patients received treatment successively. BRONJ: bisphosphonate-related osteonecrosis of the jaw; BP: bisphosphonate.